Share on

Asia Pacific Rubella Vaccine Market Research Report - Segmented By End User & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2024 to 2029)

Published: March, 2023
ID: 6182
Pages: 145
Formats: report pdf report excel report power bi report ppt

Asia Pacific Rubella Vaccine Market Size  (2024 to 2029)

As per the research report, the size of the Asia Pacific Rubella Vaccine (Human Diploid Cell) Market was valued at USD 46.69 billion in 2024 and is expected to reach USD 66.77 billion by 2029 at 7.41% CAGR during the forecast period 2024 to 2029.

The increased incidence of rubella infection and the increase in condition resulting in congenital disabilities known as congenital rubella syndrome are the major factors driving the market growth, estimated to further increase the APAC rubella vaccine market in the years to come.

The efforts of vaccine manufacturers to partner with organizations such as UNICEF, WHO, and the GAVI to improve the immunization programs of these organizations are driving the growth of the rubella vaccine market. These joint initiatives help reach large populations, especially in developing and underdeveloped countries of the APAC region. Government initiatives for successful vaccination programs to reduce child mortality and genetic deformity rates underscore the growing market for rubella vaccines. In addition, the governments of under-developed countries are working to eradicate bacterial diseases, which represent a heavy economic burden.

A high level of air pollution and hygiene awareness to prevent the spread of germs to a large population in developing and underdeveloped countries is a crucial factor in airborne viral diseases. For example, according to India's serum institute, around 40-45% of childbearing age women were susceptible to Rubella infection. In addition, it observed that over 2 lakh babies were born with congenital disabilities caused due to rubella infection during pregnancy in the Indian sub-continent.

Many local government authorities are focusing on increasing the production of MMR vaccines with lesser side effects and more efficacy. It is supported by government-aided funds for R&D activities for vaccines and improved healthcare education for the population.

However, some of the factors hampering the APAC rubella vaccine market's growth are vaccine-related reactions, especially allergies and the underperformance with high selectivity of human diploid cells during the manufacture of rubella vaccines.

This research report on the APAC Rubella Vaccine Market has been segmented and sub-segmented into the following categories:

By End User:

  • Pediatric Rubella Vaccine
  • Adult Rubella Vaccine
  • Traveler Rubella Vaccine

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia-Pacific region is emerging as a critical market for rubella vaccines and will continue to grow significantly in the years to come. The India rubella vaccine market will grow owing to raising awareness among low-income people about rubella infection and their complications. Coupled with a growing number of free government-run immunization programs will boost the market growth.

Ministry of Health and Family Welfare campaigns aim to immunize 41 million children in India. The first phase of the campaign ran successfully in 2017, completing the initiative across these five states, namely Karnataka, Lakshadweep, Tamil Nadu, Goa, and Puducherry. This campaign was conducted in schools, community centers, and other health facilities where more than 3.35 million children have been immunized, reaching over 97.5% of the target age group.

Many key market players and governmental and non-governmental agencies are funding the development of the MMR vaccines. The Chinese rubella vaccine market is implementing awareness programs and campaigns to prevent the spread of the disease. The local government has solid regulations and patient safety guidelines, aiming to eradicate the disease for long-term impact, and is expected to have better growth opportunities during the forecast period.

KEY MARKET PLAYERS

The Top Companies in the APAC Rubella Vaccine Market profiled in the report are Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample